Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Danny Thacker

Physician Assistant, Medical Frankfort, KY Physician Assistant

NPI 1205139631 CMS profile 11059381

279 Kings Daughters Dr, Suite 204, Frankfort, KY 40601

Open in the dashboard

General payments

$10,717

679 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danny Thacker of Frankfort, KY is reported in the CMS Open Payments database as having received $10,717 across 679 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,898 114
2024 General $2,095 120
2023 General $2,458 147
2022 General $2,427 168
2021 General $1,839 130

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danny Thacker
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Danny Thacker were reported at $1,898. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Danny Thacker Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $1,839 $156 $41–$563 $132
2022 $2,427 $185 $55–$649 $149
2023 $2,458 $199 $58–$717 $160
2024 $2,095 $206 $62–$740 $164
2025 $1,898 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $1,405 88 payments
  2. Novartis Pharmaceuticals Corporation $1,332 91 payments
  3. AstraZeneca Pharmaceuticals LP $1,153 59 payments
  4. Janssen Pharmaceuticals, Inc $1,136 96 payments
  5. Amgen Inc. $813 50 payments
  6. Pfizer Inc. $555 50 payments
  7. Merck Sharp & Dohme Corporation $548 33 payments
  8. Bayer HealthCare Pharmaceuticals Inc. $525 32 payments
  9. Novo Nordisk Inc $509 29 payments
  10. E.R. Squibb & Sons, L.L.C. $508 30 payments
  11. Other $2,234 121 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,517 675 payments
  2. Education $200 4 payments
Products named General payments · program years 2021–2025
  1. LifeVest $1,405 88 payments
  2. XARELTO $1,153 97 payments
  3. FARXIGA $767 40 payments
  4. Repatha $736 45 payments
  5. VERQUVO $663 40 payments
  6. LEQVIO $568 34 payments
  7. Kerendia $525 32 payments
  8. Ozempic $407 24 payments
  9. NEXLETOL $389 24 payments
  10. ENTRESTO $385 30 payments
  11. Other $4,493 267 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 77 drugs

Part D claims

7,426

Median for Physician Assistant: 241

Drug cost

$1,750,726

Median for Physician Assistant: $4,110

Branded share of claims

34.8%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 386 $448,031
Xarelto Rivaroxaban Brand 306 $408,818
Entresto Sacubitril/Valsartan Brand 144 $213,123
Repatha Sureclick Evolocumab Brand 137 $202,936
Farxiga Dapagliflozin Propanediol Brand 79 $91,131
Praluent Pen Alirocumab Brand 38 $43,685
Leqvio Inclisiran Sodium Brand 13 $42,190
Brilinta Ticagrelor Brand 36 $39,454
Multaq Dronedarone Hcl Brand 14 $32,171
Kerendia Finerenone Brand 18 $31,653

The 10 drugs with the highest cost, of 77 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$33,577

Medicare's payments for the services billed

Medicare patients

251

Average age 75

Services billed

865

134 women, 117 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 50%
Arthritis 41%
Atrial fibrillation 34%
Diabetes 33%
Chronic kidney disease 31%
Heart failure 24%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
$239 79 —
Repatha
$201 137 —
LEQVIO
$163 13 —
ENTRESTO
$135 144 —
VERQUVO
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

679 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record